Cognitive functioning and cannabis use in first-episode psychosis

References

• Degenhardt L, Ferrari AJ, Calabria B, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One. 2013;8(10):e76635.
   PubMed Web of Science ®Google Scholar
• Karjalainen K, Pekkanen N, Hakkarainen P. Drug use and drug attitudes among Finns – Drug-related population surveys in Finland 1992–2018. Finnish Institute for Health and Welfare (THL). Report 2/2020. 133 pages. Helsinki, Finland 2020.
   Google Scholar
• Russell C, Rueda S, Room R, et al. Routes of administration for cannabis use - basic prevalence and related health outcomes: a scoping review and synthesis. Int J Drug Policy. 2018;52:87–96.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Charlson F, Ferrari A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Psychiatry. 2018;5(12):987–1012.
   PubMed Web of Science ®Google Scholar
• Peacock A, Leung J, Larney S, et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction. 2018;113(10):1905–1926.
   PubMed Web of Science ®Google Scholar
• Hasin DS, Kerridge BT, Saha TD, et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the national epidemiologic survey on alcohol and related conditions-III. Am J Psychiatry. 2016;173(6):588–599.
   PubMed Web of Science ®Google Scholar
• Schimmelmann BG, Conus P, Cotton SM, et al. Cannabis use disorder and age at onset of psychosis–a study in first-episode patients. Schizophr Res. 2011;129(1):52–56.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292–297.
   PubMed Web of Science ®Google Scholar
• Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427–436.
   PubMed Web of Science ®Google Scholar
• Barnett JH, Werners U, Secher SM, et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry. 2007;190:515–520.
   PubMed Web of Science ®Google Scholar
• Sara G, Burgess P, Malhi GS, et al. Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophr Res. 2013;147(2-3):216–222.
   PubMed Web of Science ®Google Scholar
• Arranz B, Safont G, Corripio I, et al. Substance use in patients with First-Episode psychosis: is gender relevant? J Dual Diagn. 2015; 11(3-4):153–160.
   PubMed Web of Science ®Google Scholar
• Brunette MF, Mueser KT, Babbin S, Meyer-Kalos P, et al. Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophr Res. 2018;194:4–12.
   PubMed Web of Science ®Google Scholar
• Kamali M, McTigue O, Whitty P, et al. Lifetime history of substance misuse in first-episode psychosis: prevalence and its influence on psychopathology and onset of psychotic symptoms. Early Interv Psychiatry. 2009;3(3):198–203.
   PubMed Web of Science ®Google Scholar
• Stone JM, Fisher HL, Major B, MiData Consortium, et al. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med. 2014;44(3):499–506.
   PubMed Web of Science ®Google Scholar
• Tosato S, Lasalvia A, Bonetto C, et al. The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the psychosis incident cohort outcome study (PICOS). J Psychiatr Res. 2013;47(4):438–444.
   PubMed Web of Science ®Google Scholar
• Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population-a meta-analysis of 31 studies . BMC Psychiatry. 2014; 14:136.
   PubMed Web of Science ®Google Scholar
• Sideli L, Quigley H, La Cascia C, et al. Cannabis use and the risk for psychosis and affective disorders. J Dual Diagn. 2020; 16(1):22–42.
   PubMed Web of Science ®Google Scholar
• Shalit N, Lev-Ran S. Does cannabis use increase anxiety disorders? A literature review. Curr Opin Psychiatry. 2020;33(1):8–13.
   PubMed Web of Science ®Google Scholar
• Broyd SJ, van Hell HH, Beale C, et al. Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biol Psychiatry. 2016; 79(7):557–567.
   PubMed Web of Science ®Google Scholar
• Hoch E, Lorenzetti V. Mapping and mitigating the health risks of legalizing recreational cannabis use: a call for synergy between research and policy. World Psychiatry. 2020;19(2):189–191.
   PubMed Web of Science ®Google Scholar
• Green MF, Horan WP, Lee J. Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psychiatry. 2019;18(2):146–161.
   PubMed Web of Science ®Google Scholar
• Engen MJ, Simonsen C, Melle I, et al. Cognitive functioning in patients with first-episode psychosis stratified by level of negative symptoms: a 1-year follow-up study. Psychiatry Res. 2019;281:112554.
   PubMed Web of Science ®Google Scholar
• Vytal K, Cornwell B, Arkin N, et al. Describing the interplay between anxiety and cognition: from impaired performance under low cognitive load to reduced anxiety under high load. Psychophysiology. 2012;49(6):842–852.
   PubMed Web of Science ®Google Scholar
• Lindgren M, Birling H, Kieseppä T, et al. Is cognitive performance associated with anxiety and depression in first-episode psychosis? J Affect Disord. 2020a;263:221–227.
   PubMed Web of Science ®Google Scholar
• Cuesta MJ, Sánchez-Torres AM, Lorente-Omeñaca R, et al. Lifetime cannabis use and cognition in psychosis spectrum disorders. In V. R. Preedy (Ed.), Handbook of cannabis and related pathologies: Biology, pharmacology, diagnosis, and treatment. 2017. p. 44–52. Elsevier Academic Press.
   Google Scholar
• Hanna RC, Shalvoy A, Cullum CM, et al. Cognitive function in individuals with psychosis: moderation by adolescent cannabis Use. Schizophr Bull. 2016;42(6):1496–1503.
   PubMed Web of Science ®Google Scholar
• Power BD, Dragovic M, Badcock JC, et al. No additive effect of cannabis on cognition in schizophrenia. Schizophr Res. 2015;168(1-2):245–251.
   PubMed Web of Science ®Google Scholar
• McCleery A, Addington J, Addington D. Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up. Schizophr Res. 2006;88(1-3):187–191.
   PubMed Web of Science ®Google Scholar
• Wobrock T, Sittinger H, Behrendt B, et al. Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2007;257(4):203–210.
   PubMed Web of Science ®Google Scholar
• Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci. 2003;28(1):48–54.
   PubMed Web of Science ®Google Scholar
• Wobrock T, Falkai P, Schneider-Axmann T, et al. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res. 2013;147(1):132–139.
   PubMed Web of Science ®Google Scholar
• Mata I, Rodríguez-Sánchez JM, Pelayo-Terán JM, et al. Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. Psychol Med. 2008;38(9):1257–1266.
   PubMed Web of Science ®Google Scholar
• Weibell MA, Johannessen JO, Auestad B, et al. Early substance use cessation improves cognition-10 years outcome in first-episode psychosis patients. Front Psychiatry. 2019; Jul 1210:495.
   PubMed Web of Science ®Google Scholar
• Karpov B, Kieseppä T, Lindgren M, et al. Anxiety symptoms in first-episode psychosis. Early Interv Psychiatry. 2020; 15(3):569–576.
   PubMed Web of Science ®Google Scholar
• Ventura J, Lukoff D, Nuechterlein KH, et al. Brief psychiatric rating scale (BPRS) expanded version: Scales, anchor points, and administration manual. Int J Meth Psychiatric Res. 1993;3:227–243.
   Google Scholar
• First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for dsm-iv-tr axis I disorders, research version, patient edition. (SCID-I/P). Biometrics Research, New York State Psychiatric Institute, New York, NY 2002. Revision: January 2007.
   Google Scholar
• Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry. 1989;155(S7):49–58.
   Google Scholar
• Corcoran R, Mercer G, Frith CD. Schizophrenia, symptomatology and social inference: investigating "theory of mind" in people with schizophrenia. Schizophr Res. 1995;17(1):5–13.
   PubMed Web of Science ®Google Scholar
• Lindgren M, Torniainen-Holm M, Heiskanen I, et al. Theory of mind in a first-episode psychosis population using the hinting task. Psychiatry Res. 2018;263:185–192.
   PubMed Web of Science ®Google Scholar
• Li AWY, Hui CLM, Lee EHM, et al. Gender differences in correlates of cognition in first-episode psychosis. Psychiatry Res. 2019;271:412–420.
   PubMed Web of Science ®Google Scholar
• IBM SPSS Statistics for Windows, Version 22.0. Released 2015. Armonk, NY: IBM Corp.
   Google Scholar
• Yoo W, Mayberry R, Bae S, et al. A study of effects of multicollinearity in the multivariable analysis. Int J Appl Sci Technol. 2014;4(5):9–19.
   PubMedGoogle Scholar
• Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. Drug Test Anal. 2014; Jan-Feb6(1-2):39–45.
   PubMed Web of Science ®Google Scholar
• Karila L, Roux P, Rolland B, et al. Acute and long-term effects of cannabis use: a review. Curr Pharm Des. 2014;20(25):4112–4118.
   PubMed Web of Science ®Google Scholar
• Marconi A, Di Forti M, Lewis CM, et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262–1269.
   PubMed Web of Science ®Google Scholar
• Cosker E, Schwitzer T, Ramoz N, et al. The effect of interactions between genetics and cannabis use on neurocognition. A review. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:95–106.
   PubMed Web of Science ®Google Scholar
• French L, Gray C, Leonard G, et al. Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence. JAMA Psychiatry. 2015;72(10):1002–1011.
   PubMed Web of Science ®Google Scholar
• Battistella G, Fornari E, Annoni JM, et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology. 2014;39(9):2041–2048.
   PubMed Web of Science ®Google Scholar
• Bloomfield MAP, Hindocha C, Green SF, et al. The neuropsychopharmacology of cannabis: a review of human imaging studies. Pharmacol Ther. 2019; 195:132–161.
   PubMed Web of Science ®Google Scholar
• Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol. 2012;20(5):420–429.
   PubMed Web of Science ®Google Scholar
• Menendez-Miranda I, Garcia-Alvarez L, Garcia-Portilla MP, et al. History of lifetime cannabis use is associated with better cognition and worse real-world functioning in schizophrenia spectrum disorders. Eur Addict Res. 2019;25(3):111–118.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Koren D, Reichenberg A, et al. Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull. 2006;32(2):250–258.
   PubMed Web of Science ®Google Scholar
• Huang M, Huang Y, Yu L, et al. Relationship between negative symptoms and neurocognitive functions in adolescent and adult patients with first-episode schizophrenia. BMC Psychiatry. 2016;16(1):344.
   PubMedGoogle Scholar
• Lindgren M, Holm M, Kieseppä T, et al. Neurocognition and social cognition predicting 1-year outcomes in first-episode psychosis. Front Psychiatry. 2020b;11:603933.
   PubMed Web of Science ®Google Scholar
• Pinkham AE, Harvey PD, Penn DL. Social cognition psychometric evaluation: results of the final validation study. Schizophr Bull. 2018;44(4):737–748.
   PubMed Web of Science ®Google Scholar
• Cuesta MJ, Sánchez-Torres AM, Cabrera B, et al. Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPs cog study. Schizophr Res. 2015;164(1-3):65–73.
   PubMed Web of Science ®Google Scholar
• Karson C, Duffy RA, Eramo A, et al. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016; 12:57–67.
   PubMed Web of Science ®Google Scholar
• Waterreus A, Badcock JC, Di Prinzio P, et al. The impact of current cannabis use on general cognitive function in people with psychotic illness. Schizophr Res. 2017;190:164–171.
   PubMed Web of Science ®Google Scholar